SS-31 Peptide Research: Cardiolipin, Mitochondria and FDA Status

SS-31 peptide research occupies a place almost no other research peptide reaches: one form of this four-amino-acid molecule is now an FDA-approved prescription medicine, while the same molecule continues to be studied in laboratories as a tool for probing mitochondrial membrane biology. SS-31 — known in clinical development as elamipretide, and earlier as MTP-131 and Bendavia — is a synthetic tetrapeptide designed to concentrate inside mitochondria and bind cardiolipin, the signature phospholipid of the inner mitochondrial membrane. On September 19, 2025, the U.S. Food and Drug Administration granted accelerated approval to elamipretide, under the brand name Forzinity, to improve muscle strength in adult and pediatric patients with Barth syndrome weighing at least 30 kg — the first FDA-approved treatment for Barth syndrome and the first approved mitochondria-targeted therapy of its kind.

That approval makes SS-31 peptide research unusually instructive for laboratory researchers. It is also frequently misunderstood. The approval is narrow, accelerated, and based on an intermediate endpoint. The pivotal randomized trials behind it missed their primary endpoints. And a prescription product approved for one ultra-rare disease is not the same thing as research-grade material, which is supplied strictly for laboratory research use only. This article separates what is established from what remains investigational.

What SS-31 is

SS-31 is the lead compound of the Szeto-Schiller (SS) peptide family, developed from work by Hazel Szeto at Cornell and Peter W. Schiller at the Montreal Clinical Research Institute. Its sequence is D-Arg-Dmt-Lys-Phe-NH2, where Dmt is 2′,6′-dimethyl-L-tyrosine, a non-standard tyrosine derivative. Four features of that short sequence explain nearly all of its behavior:

• Alternating aromatic and basic residues. The pattern of aromatic side chains and positively charged residues gives the molecule a net charge of +3 at physiological pH while remaining lipophilic enough to cross cell membranes without a transporter or energy input.
• A D-amino acid at position 1. D-arginine, rather than the usual L-form, improves resistance to peptidase breakdown at that end of the molecule.
• A modified tyrosine. The two extra methyl groups on Dmt change how that residue interacts with membrane lipids and proteins compared with ordinary tyrosine.
• A capped C-terminus. The terminal amide (-NH2) removes a negative charge and further stabilizes the peptide.

The basic identity data researchers use to verify the material are summarized below.

Because the molecule is so small, identity testing matters more, not less: a four-residue peptide leaves very little structural margin for a synthesis error to hide in, which is why mass spectrometry confirmation is central to reading its certificate of analysis, as discussed below.

The cardiolipin mechanism at the center of SS-31 peptide research

Most peptides in research catalogs work by binding a receptor. SS-31 does not. Its target is a lipid.

Why cardiolipin matters

Cardiolipin is found almost exclusively in the inner mitochondrial membrane, where it can make up roughly a fifth of membrane lipid. It is not passive packing material. Cardiolipin:

• holds the folds of the inner membrane — the cristae — in their working shape;
• anchors and organizes the electron transport chain complexes and their supercomplexes;
• binds cytochrome c, the mobile electron carrier that also becomes a trigger for programmed cell death when released; and
• helps maintain the membrane potential that drives ATP synthesis.

When cardiolipin is damaged — oxidized, lost, or abnormally remodeled — cristae flatten, electron transport becomes less efficient, more electrons leak to oxygen as reactive oxygen species (ROS), and ATP output falls. That chain of events is a recurring feature of mitochondrial dysfunction across very different disease models, which is why a cardiolipin-binding molecule attracted such broad research interest.

What binding does

SS-31 partitions into the inner mitochondrial membrane and concentrates there by an estimated 1,000- to 5,000-fold over its concentration elsewhere in the cell, driven by electrostatic attraction to negatively charged cardiolipin head groups combined with hydrophobic interaction from its aromatic residues. Once bound, published mechanistic work describes several linked effects:

1. Cristae and supercomplex stabilization. The peptide helps preserve inner-membrane architecture, keeping respiratory complexes organized so electron flow stays efficient.
2. Reduced electron leak. Lower ROS output appears to be largely a consequence of better-coupled electron transport, not simple free-radical scavenging. Early descriptions of SS-31 as a direct antioxidant have been revised by later structural and biophysical work: the primary action is cardiolipin binding and membrane stabilization, with reduced oxidative stress downstream.
3. Modulation of cytochrome c. Bound at the cardiolipin interface, the peptide influences cytochrome c’s peroxidase activity — the reaction that oxidizes cardiolipin and helps set apoptosis in motion — which is one route by which it reduces cell-death signaling in preclinical models.
4. Protection of cardiolipin itself. By occupying the interface, SS-31 shields cardiolipin from peroxidation, preserving the lipid the membrane depends on.

The important research point is what SS-31 does not do: it does not replace missing cardiolipin, increase cardiolipin synthesis, or repair the genetic defects that cause cardiolipin disorders. In Barth syndrome — caused by mutations in the TAFAZZIN gene, whose protein remodels cardiolipin — studies report an improved monolysocardiolipin-to-cardiolipin ratio under long-term treatment, a change in lipid composition consistent with better protection of mature cardiolipin, not new synthesis. Researchers should model SS-31 as an occupancy-dependent stabilizer of the cardiolipin–protein interface: its effects are expected while it is present at the membrane, not as a permanent correction.

Why Barth syndrome was the proving ground

Barth syndrome is an ultra-rare, X-linked mitochondrial disorder affecting an estimated 150 people in the United States, primarily males. TAFAZZIN mutations leave cardiolipin abnormally remodeled, and the clinical picture follows the mitochondria: cardiomyopathy, skeletal muscle weakness, exercise intolerance, debilitating fatigue, recurrent infections, and delayed growth, with substantially reduced life expectancy.

Mechanistically, it is the most direct test of the cardiolipin hypothesis available in human medicine: if a cardiolipin-binding peptide helps anywhere, it should help in a disease that is, at root, a cardiolipin-remodeling disease. That logic carried the program through an unusually difficult clinical path.

What the clinical trials actually found

An honest account of SS-31 peptide research has to hold two facts at once: the human dataset is one of the most mature of any mitochondria-targeted peptide, and its largest randomized trials missed their primary endpoints.

Reading the approval correctly

FDA’s September 19, 2025 decision was an accelerated approval, a pathway that allows approval based on an intermediate clinical endpoint reasonably likely to predict clinical benefit. For Forzinity, that endpoint was improvement in knee extensor muscle strength, drawn from the TAZPOWER program and its long-term extension together with natural-history comparison data. The label states the indication plainly: to improve muscle strength in adult and pediatric patients with Barth syndrome weighing at least 30 kg. Continued approval is contingent on verification of clinical benefit in a confirmatory trial; a confirmatory study was in preparation and its design was presented in 2026. Accelerated approvals can be withdrawn if confirmatory evidence fails to verify benefit.

One year on, the sponsor — Stealth BioTherapeutics, now operating as Mighty Therapeutics — reported in October 2026 that the Barth syndrome launch had continued through its first year, with commercial availability since December 2025 and ongoing pipeline work in other mitochondrial indications. That is commercial and pipeline news, not new efficacy evidence, and researchers should keep the two categories separate.

The balanced summary is this: SS-31 pairs a strong, well-characterized mechanism with the most mature clinical program in its class — and that program produced a narrow, conditional approval for one ultra-rare disease after its pivotal randomized endpoints were missed. For every other condition it is popularly associated with, it remains investigational and unproven.

SS-31 vs MOTS-c: two mitochondrial peptides, two different logics

Researchers often shelve SS-31 next to MOTS-c because both are described as “mitochondrial peptides.” The resemblance ends at the organelle.

Choosing between them is a question about which level of mitochondrial biology an experiment is testing — membrane structure or metabolic signaling — not about which is “stronger.”

Practical laboratory considerations

For researchers working with SS-31 as a laboratory material, several compound-specific points deserve attention:

• Identity confirmation is non-negotiable. The expected molecular weight is 639.8 g/mol for the free base. A mass spectrometry result that does not match should stop the experiment before it starts; our guide to peptide mass spectrometry explains how charge-state deconvolution confirms a small peptide’s identity.
• Purity is a chromatogram, not a slogan. With only four residues, the realistic related impurities are short deletion and truncated sequences and oxidized species, which reversed-phase HPLC separates and quantifies. Read the actual trace using the method in our HPLC purity testing guide, and cross-check it against the batch COA using how to read a certificate of analysis.
• Salt form affects net content. Research material may be supplied as different salt forms, which changes the fraction of mass that is peptide versus counter-ion. Net peptide content on the COA — not headline vial mass — is the number quantitative work should be based on.
• The Dmt residue is a synthesis checkpoint. 2′,6′-dimethyltyrosine is not a standard building block. Its correct incorporation is exactly the kind of detail MS/MS fragmentation can verify and a generic purity percentage cannot.
• Storage follows standard lyophilized practice. Keep unopened lyophilized material cold, sealed, dry, and protected from light, and avoid repeated freeze-thaw of prepared solutions; see our peptide storage best practices for the underlying reasoning.
• Prescription status changes nothing about research material. Forzinity is a manufactured prescription drug for a defined patient population. An SS-31 research peptide from a research supplier is a different product, made and labeled for laboratory research only, and the approval of the former confers no status, indication, or quality claim on the latter.

Newer researchers may also find our overview of what peptides are useful background before working with any tetrapeptide tool compound.

Frequently asked questions

Is SS-31 FDA-approved? Elamipretide was FDA-approved on September 19, 2025 under the brand name Forzinity, under accelerated approval, for one indication: improving muscle strength in patients with Barth syndrome weighing at least 30 kg. It is not FDA-approved for any other condition, and research-grade SS-31 is not an approved drug product of any kind.

Is SS-31 the same as elamipretide? Yes. SS-31 is the research designation; elamipretide is the generic (INN) name used in clinical development. MTP-131 and Bendavia are earlier development names for the same molecule.

How is SS-31 different from a typical antioxidant? Later mechanistic work indicates its primary action is binding cardiolipin and stabilizing the inner mitochondrial membrane and respiratory supercomplexes. Reduced reactive oxygen species follow from better-coupled electron transport; it is not principally a free-radical scavenger, and its Dmt residue’s chemistry is only part of the story.

Did the big SS-31 trials succeed? Mixed. The randomized phase of TAZPOWER and the Phase 3 MMPOWER-3 trial in primary mitochondrial myopathy both missed their primary endpoints. Long-term open-label extension data in Barth syndrome showed functional and strength gains, and FDA based its accelerated approval on knee extensor muscle strength as an intermediate endpoint, with a confirmatory trial still required.

Is SS-31 approved in Europe? The September 2025 approval discussed here is a U.S. FDA decision for the prescription product. Researchers outside the U.S. should check their own regulator’s current listings rather than assuming equivalent status, and research material remains research-use-only regardless of jurisdiction.

What should a laboratory verify before using SS-31 in an experiment? Identity by mass spectrometry against the expected 639.8 g/mol, batch-specific HPLC purity with the chromatogram available, the stated salt form and net peptide content, and storage history. The full framework is in our guide to reading a COA, linked above.

Related in the Apex shop: SS-31 research peptide — supplied strictly for laboratory research use.

Research Use Only disclaimer: All Apex Bio Industries products, including SS-31, are supplied strictly for laboratory research use only. They are not intended for human or veterinary use, consumption, diagnosis, or treatment of any condition, and nothing in this article is medical advice or a recommendation for use outside a laboratory research setting. The FDA-approved prescription product discussed above (Forzinity) is a separate drug product available only by prescription for its labeled indication; references to its approval and clinical program are provided solely as research context.